Novartis' (NVS +0.3%) RLX030 drug cut the number of deaths in patients with acute heart failure...

|About: Novartis AG (NVS)|By:, SA News Editor

Novartis' (NVS +0.3%) RLX030 drug cut the number of deaths in patients with acute heart failure in a Phase III trial. (PR)